Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) had its target price decreased by stock analysts at Canaccord Genuity Group from $25.00 to $23.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Canaccord Genuity Group's target price would suggest a potential upside of 154.71% from the stock's previous close.
A number of other research firms also recently commented on ZVRA. Cantor Fitzgerald reissued an "overweight" rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. William Blair raised Zevra Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Monday, September 30th. JMP Securities assumed coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an "outperform" rating and a $17.00 target price on the stock. Finally, Roth Mkm boosted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $21.00.
Read Our Latest Report on ZVRA
Zevra Therapeutics Stock Performance
Zevra Therapeutics stock traded up $0.37 during mid-day trading on Thursday, hitting $9.03. 941,388 shares of the company's stock traded hands, compared to its average volume of 544,623. The firm has a 50 day moving average price of $7.97 and a 200 day moving average price of $6.44. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The company has a market cap of $475.16 million, a PE ratio of -4.57 and a beta of 1.93. Zevra Therapeutics has a one year low of $4.18 and a one year high of $9.21.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. The business had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period in the previous year, the firm earned ($0.15) EPS. On average, equities analysts forecast that Zevra Therapeutics will post -1.63 EPS for the current year.
Hedge Funds Weigh In On Zevra Therapeutics
Several large investors have recently made changes to their positions in ZVRA. MetLife Investment Management LLC raised its holdings in Zevra Therapeutics by 8.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company's stock valued at $159,000 after acquiring an additional 1,717 shares in the last quarter. City State Bank raised its holdings in Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock valued at $91,000 after acquiring an additional 2,452 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock valued at $48,000 after acquiring an additional 5,940 shares in the last quarter. Finally, IFG Advisors LLC raised its holdings in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company's stock valued at $183,000 after acquiring an additional 7,700 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company's stock.
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Featured Articles
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
